RecruitingPhase 2NCT06679985

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Sponsor

Coherus Oncology, Inc.

Enrollment

72 participants

Start Date

Dec 20, 2024

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma

Summary

The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new drug combination for liver cancer (hepatocellular carcinoma) that cannot be surgically removed. The combination includes an experimental drug (casdozokitug) plus two existing cancer drugs (toripalimab, an immunotherapy, and bevacizumab, which cuts off blood supply to tumors). **You may be eligible if...** - You have advanced liver cancer that is confirmed by biopsy or meets recognized diagnostic criteria - Your cancer cannot be removed by surgery or local treatments, or it has come back after those treatments - You have at least one measurable tumor that has not been previously treated - You have not yet received systemic (whole-body) drug therapy for liver cancer **You may NOT be eligible if...** - You have previously received any systemic treatment for liver cancer - You have a rare form of liver cancer (fibrolamellar, sarcomatoid, or mixed with bile duct cancer) - You have significant fluid buildup in your abdomen (ascites) or around your heart or lungs that cannot be controlled - You have previously been treated with drugs targeting the IL-27 protein Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCasdozokitug

Solution for infusion

DRUGToripalimab

Solution for infusion

DRUGBevacizumab

Solution for infusion

Locations(44)

Mayo Clinic - Scottsdale

Scottsdale, Arizona, United States

University of Arizona - Cancer Center

Tucson, Arizona, United States

Beverly Hills Cancer Center

Beverly Hills, California, United States

City of Hope

Duarte, California, United States

City of Hope at Irvine Lennar

Irvine, California, United States

Cancer & Blood Specialty Clinic

Lakewood, California, United States

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States

Sarcoma Oncology Center

Santa Monica, California, United States

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States

The Winship Cancer Institute Emory University

Atlanta, Georgia, United States

Mountain States Tumor Institute at St. Luke's Regional Medical Center

Boise, Idaho, United States

University of Kansas Cancer Center

Kansas City, Kansas, United States

UofL Health Brown Cancer Center

Louisville, Kentucky, United States

University of Mississippi Medical Center

Jackson, Mississippi, United States

Christus St. Vincent Regional Medical Center

Santa Fe, New Mexico, United States

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

New York, New York, United States

Montefiore Medical Center

The Bronx, New York, United States

University of North Carolina (UNC) - Chapel Hill

Chapel Hill, North Carolina, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)

Columbus, Ohio, United States

University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Prisma Health Cancer Institute

Greenville, South Carolina, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Virginia Oncology Associates

Norfolk, Virginia, United States

UW Carbone Cancer Center - Cancer Connect

Madison, Wisconsin, United States

Royal Brisbane and Women's Hospital

Herston, Brisbane, Australia

Bankstown-Lidcombe Hospital

Bankstown, New South Wales, Australia

Monash Health

Melbourne, Victoria, Australia

St Vincent's Hospital Sydney

Darlinghurst, Australia

Linear Clinical Research

Nedlands, Australia

Sunnybrook Health Sciences Centre - Bayview Campus

Toronto, Ontario, Canada

Princess Margaret Hospital

Toronto, Ontario, Canada

Prince of Wales Hospital

Shatin, New Territories, Hong Kong

Queen Mary Hospital

Hong Kong, Pok Fu Lam, Hong Kong

Humanity & Health Clinical Trial Centre

Hong Kong, Hong Kong

National Cancer Centre Singapore

Singapore, Singapore

Tan Tock Seng Hospital

Singapore, Singapore

Curie Oncology

Singapore, Singapore

China Medical University Hospital

Taichung, Taichung City, Taiwan

National Cheng Kung University Hospital

Tainan, Tainan City, Taiwan

National Taiwan University Hospital

Tainan, Taipei City, Taiwan

Taipei Veterans General Hospital

Taipei, Taipei City, Taiwan

Chi Mei Medical Center

Tainan, Taiwan

Linkou Chang Gung Memorial Hospital (CGMHLK)

Taoyuan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06679985

Related Trials

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

NCT0609677961 locations

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT044727671 location

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

NCT069022461 location

SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

NCT072747741 location